Application of FIS to prostate cancer cells inhibits mTOR activity and reduces the levels of Raptor, Rictor, PRAS40, and GbL, resulting in the loss of formation of mTOR complexes (mTORC)1/2. Here, MTOR is linked to prostate cancer.